Innovations in women’s health genetic testing
From prenatal genetic testing that paved the way for earlier cancer recurrence testing, Natera is continuing to innovate its technology to broaden applications in women’s health that enable better health outcomes.
Trusted expertise adapted to detect tumor DNA
Pioneering NIPT technology now applied to cancer recurrence detection and monitoring
Natera introduced its pioneering single nucleotide polymorphism-based (SNP-based) NIPT 10+ years ago, which can distinguish maternal from fetal cell-free DNA (cfDNA). Now, this technology has been adapted to detect circulating tumor DNA (ctDNA) in those living with cancer.
Natera’s focus on rigorous clinical validation in prenatal testing continues with cancer genomics and precision medicine and is applied to each test in its portfolio. Natera is and will remain committed to extensively validating our offerings and publishing the data for scientific record.
Detecting cancer recurrence earlier
Signatera™ is the first tumor-informed molecular residual disease (MRD) test for individualized cancer care. It assesses the presence or absence of circulating tumor DNA (ctDNA) cells.
It’s used to detect cancer recurrence (or relapse) earlier, at the molecular level, than standard of care tools and for treatment response monitoring to indicate whether a therapeutic intervention is working or cancer is coming back.
See how Natera’s ctDNA test Signatera™ works
10.5 months earlier
median lead time in breast cancer recurrence detection over standard imaging1
2x the sensitivity
in detecting ovarian cancer relapse compared to CA-125, the most commonly used biomarker for ovarian cancer2,3
As early as 6 weeks
into treatment to identify response to immunotherapy in gynecologic cancers4Recurrence monitoring and treatment response
Danielle’s Story
Danielle’s molecular breast cancer recurrence was detected by Signatera™ so that she and her doctor could act quickly. Hear her story and how recurrence monitoring is helping her live her life.
Angela’s Story
Angela faced many questions throughout her journey with breast cancer. Listen to how she was proactive in asking her doctor about Signatera™ to help monitor for recurrence and assess treatment response.
Creating the most validated MRD test
There are 100+ peer-reviewed studies on Signatera™ across multiple indications, including breast, gynecologic, colorectal, bladder, and lung cancers, including 200K+ patients.
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Creating the most validated MRD test
There are 100+ peer-reviewed studies on Signatera™ across multiple indications, including breast, gynecologic, colorectal, bladder, and lung cancers, including 200K+ patients.
Lajos Pusztai, MD, DPhil
Professor of Medicine (Medical Oncology); Co-Leader, Genetics, Genomics and Epigenetics Research Program, Yale Cancer Center, Yale School of Medicine
Investing in innovations in personalized genetic testing
R&D INVESTMENTS
400 MILLION
PEER-REVIEWED PUBLICATIONS
250+
PATIENT SAMPLES
~10 MILLION
Learn more about Natera’s latest innovations
1Shaw JA, et al. Serial postoperative ctDNA monitoring for early detection of breast cancer recurrence. Poster presented at: ASCO; June 3-7, 2022; Chicago, IL.
2Hou et al. Gynecol Oncol. 2022; 167:334-341
3Chapman et al. Poster presented at 2021 AACR Annual Meeting.
4Bratman et al. Nature Cancer. 2020; 1(9):873-881.